OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
XINT$0.2355

Xintela AB

Biotechnology & Medical ResearchVerified

Xintela AB operates with a negative equity position of -5.27 million SEK and a cash and equivalents balance of 23.21 million SEK, indicating a liquidity cushion despite a negative net income of -48.56 million SEK. The company's market capitalization is 196.37 million SEK, with a market price of 0.228 SEK per share. The enterprise value to revenue ratio is 75.88, suggesting a high valuation relative to its revenue of 2.28 million SEK. Profitability metrics reveal a challenging financial position. The company's return on equity is 9.21%, which is unusually high given the negative net income, likely due to the negative equity base. The return on assets is -1.67%, indicating that the company is not generating returns from its asset base. The operating income is -46.68 million SEK, and the operating cash flow is -41.62 million SEK, highlighting significant operational losses. Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. However, the lack of segmental breakdown suggests a potential risk of over-reliance on a single product or market. The absence of capital expenditures indicates that the company is not investing in new projects or infrastructure, which could limit future growth. The company's growth trajectory is constrained by its current financial performance. The revenue of 2.28 million SEK is not accompanied by positive growth indicators, and the outlook for the current and next fiscal years does not show improvement. The company's negative operating cash flow and free cash flow of -41.62 million SEK and -47.96 million SEK, respectively, suggest ongoing cash burn without clear signs of a turnaround. Risk factors include a low liquidity position, as indicated by the current ratio of 0.84, and a negative equity position. The company has no immediate filing-based liquidity or dilution flags, but the negative net income and operating cash flow pose ongoing risks. The dilution potential is low, and no adjustments have been applied to the valuation metrics. Recent events and filings do not indicate any significant changes in the company's strategic direction or financial status. The absence of recent capital raising activities or major business developments suggests a period of operational stagnation.

30-day price · XINT(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyXintela AB
TickerXINT.ST
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Xintela AB is a biotechnology company focused on healthcare diagnostics, primarily generating revenue through the development and commercialization of diagnostic solutions.

Classification. Xintela is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.

Xintela AB operates with a negative equity position of -5.27 million SEK and a cash and equivalents balance of 23.21 million SEK, indicating a liquidity cushion despite a negative net income of -48.56 million SEK. The company's market capitalization is 196.37 million SEK, with a market price of 0.228 SEK per share. The enterprise value to revenue ratio is 75.88, suggesting a high valuation relative to its revenue of 2.28 million SEK. Profitability metrics reveal a challenging financial position. The company's return on equity is 9.21%, which is unusually high given the negative net income, likely due to the negative equity base. The return on assets is -1.67%, indicating that the company is not generating returns from its asset base. The operating income is -46.68 million SEK, and the operating cash flow is -41.62 million SEK, highlighting significant operational losses. Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. However, the lack of segmental breakdown suggests a potential risk of over-reliance on a single product or market. The absence of capital expenditures indicates that the company is not investing in new projects or infrastructure, which could limit future growth. The company's growth trajectory is constrained by its current financial performance. The revenue of 2.28 million SEK is not accompanied by positive growth indicators, and the outlook for the current and next fiscal years does not show improvement. The company's negative operating cash flow and free cash flow of -41.62 million SEK and -47.96 million SEK, respectively, suggest ongoing cash burn without clear signs of a turnaround. Risk factors include a low liquidity position, as indicated by the current ratio of 0.84, and a negative equity position. The company has no immediate filing-based liquidity or dilution flags, but the negative net income and operating cash flow pose ongoing risks. The dilution potential is low, and no adjustments have been applied to the valuation metrics. Recent events and filings do not indicate any significant changes in the company's strategic direction or financial status. The absence of recent capital raising activities or major business developments suggests a period of operational stagnation.
Key takeaways
  • Xintela AB is a biotechnology company with a negative equity position and significant operational losses.
  • The company's high enterprise value to revenue ratio suggests a speculative valuation.
  • The lack of capital expenditures and segmental revenue breakdown indicates limited diversification and growth potential.
  • The company's liquidity position is weak, with a current ratio below 1 and negative net income.
  • No immediate dilution or liquidity flags are present, but ongoing cash burn remains a concern.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySEK
Revenue$2.3M
Gross profit$2.3M
Operating income-$46.7M
Net income-$48.6M
R&D
SG&A
D&A
SBC
Operating cash flow-$41.6M
CapEx$0.00
Free cash flow-$48.0M
Total assets$29.0M
Total liabilities$34.3M
Total equity-$5.3M
Cash & equivalents$23.2M
Long-term debt
Valuation
Market price$0.23
Market cap$196.4M
Enterprise value$173.2M
P/E
Reported non-GAAP P/E
EV/Revenue75.9
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$5.3M
Net cash$23.2M
Current ratio0.8
Debt/Equity-0.0
ROA-1.7%
ROE9.2%
Cash conversion86.0%
CapEx/Revenue0.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricXINTActivity
Op margin-2045.7%-227.5% medp25 -1250.6% · p75 -3.5%bottom quartile
Net margin-2128.1%-194.5% medp25 -1233.8% · p75 0.8%bottom quartile
Gross margin100.0%53.0% medp25 25.9% · p75 75.7%top quartile
CapEx / revenue0.0%-8.2% medp25 -35.2% · p75 -2.5%top quartile
Debt / equity-0.0%1.2% medp25 0.0% · p75 17.4%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 23:39 UTC#2d0c1b56
Source: analysis-pipeline (hybrid)Generated: 2026-05-30 01:51 UTCJob: b7b48ff0